Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

156 results about "OSB-CoA synthetase" patented technology

MenE, the o-succinylbenzoate (OSB)-CoA synthetase from bacterial menaquinone biosynthesis, is a promising new antibacterial target. Sulfonyladenosine analogues of the cognate reaction intermediate, OSB-AMP, have been developed as inhibitors of the MenE enzymes from Mycobacterium tuberculosis (mtMenE), Staphylococcus aureus (saMenE) and Escherichia coli (ecMenE).

Structures of human histidyl-trna synthetase and methods of use

Provided are histidyl-tRNA synthetase variant polypeptides, X-ray crystallographic and NMR spectroscopy structures of HRS polypeptides, and related compositions and methods for therapy and drug discovery.
Owner:ATYR PHARM INC +1

Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Owner:PANGU BIOPHARMA

Marker-free gene deletion attenuated mutant strain of Edwardsiella tarda wild strain as well as relevant preparations and application thereof

The invention relates to a marker-free gene deletion attenuated mutant strain of an Edwardsiella tarda wild strain. The marker-free gene deletion attenuated mutant strain is an attenuated live vaccine of an Edwardsiella tarda virulent strain, which deletes the chorismic acid synthase gene aroC of the Edwardsiella tarda virulent strain, three types of secretion system response element genes of eseB, escA, eseC and eseD and an endogenous plasmid, preferably, the Edwardsiella tarda virulent strain is an Edwardsiella tarda virulent strain EIB202 with the preservation number of CCTCC No:M208068; the endogenous plasmid is a plasmid of pEIB202; and the marker-free gene deletion attenuated mutant strain of the Edwardsiella tarda virulent strain is an attenuated strain WED with the preservation number of CCTCC No:M2010278. The invention also provides relevant preparations and application of the marker-free gene deletion attenuated mutant strain. The attenuated mutant strain or relevant preparations eliminate the potential environment and safety risk of products existing in the traditional attenuated live vaccines generally and is a safe, effective and economic vaccine aiming at Edwardsiella tarda diseases of cultured fishes.
Owner:EAST CHINA UNIV OF SCI & TECH

Gene engineering bacteria capable of highly producing pleocidin and preparation method thereof

The invention discloses gene engineering bacteria capable of highly producing pleocidin and a preparation method thereof. In the gene engineering bacteria, an expression box of NDP-glucose synthesized enzyme gene gtt of NDP-4-ketone-6-deoxidation-Dglucose and an expression box of genes of NDP-glucose reductase gene gdh are integrated in genomes of Saccharopolyspora spinosa wild bacterial strains. According to fermentation validation, the fermenting units of the pleocidin of the gene engineering bacteria is increased by more than three times compared with that of the wild bacterial strains.
Owner:SHANGHAI INST OF PHARMA IND

Recombinant corynebacterium glutamicum capable of being used for highly yielding L-phenylalanine and application thereof

The invention discloses recombinant corynebacterium glutamicum capable of being used for highly yielding L-phenylalanine and a method for producing the L-phenylalanine (Phe) by fermentation and belongs to the field of metabolic engineering. According to the invention, a corynebacterium glutamicum engineering strain C.glutamicum19AF / 99TP capable of being used for highly yielding the L-Phe is obtained in a corynebacterium glutamicum type strain ATCC13032 by carrying out induction expression on the following four genes: a 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase gene, a chorismate mutase / prephenate dehydratase gene which has resistance to feedback inhibition, a transketolase gene and a phosphoenolpyruvic acid synthetase gene. A shikimic acid metabolic pathway of an L-Phe synthetic metabolic pathway is over-expressed in the C.glutamicum ATCC13032; a key enzyme gene of a chorismic acid metabolic pathway enables the yield of the L-Phe to reach 3.47g / L; two enzyme genes which combines an expression center metabolic pathway to improve a precursor enables the highest yield of the L-Phe to reach 4.86g / L; and the original strain ATCC13032 which is used as a contrast strain cannot detect accumulation of the L-Phe in the integral fermenting process.
Owner:JIANGNAN UNIV

Genetic engineering bacterium for L-theanine production and construction and application thereof

The invention belongs to the technical field of genetic engineering, and particularly relates to novel high-efficiency gamma-glutamyl methylamine synthetase and a plasmid-free genetic engineering bacterium for L-theanine production and construction and application thereof. The plasmid-free genetic engineering bacterium which performs denovo synthesis on L-theanine efficiently by taking cheap carbon sources such as glucose as a substrate is provided, escherichia coli serves as a host, and gamma-glutamyl methylamine synthase genes gmas-Mu copied three times are integrated on a genome of the escherichia coli; a glutamate dehydrogenase gene Cgl2079 is copied once; a pyruvate carboxylase gene Cgl0689 is copied once; a citrate synthase gene gltA is copied once, and the genetic engineering bacterium is obtained. After metabolic transformation of a system, the engineering bacterium can perform denovo synthesis on the L-theanine by taking the glucose as the raw material, the fermentation yieldand sugar-acid conversion rate are the highest values reported so far, in fermentation of a 5 L fermentor, the maximum production of the L-theanine can reach 60 g/L, and the sugar-acid conversion ratecan reach 40%.
Owner:TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY

Method for extracting sucrose synthase and sucrose phosphate synthase of pear fruit and activity determination method thereof

The invention belongs to the field of plant physiology, and discloses a method for extracting sucrose synthase and sucrose phosphate synthase of pear fruits and an activity determination method thereof. Small molecules such as sugar, ions and the like can be usually removed from a primary extraction enzyme solution through adding a salting-out step and a dialysis step in the extracting process of the sucrose synthase and the sucrose phosphate synthase, so that activities of the sucrose synthase and the sucrose phosphate synthase in the fruits can be accurately detected. The method provides physiological basis for disclosing accumulation differences of the sugar in the fruits, and further provides theoretical basis for improving the quality of fruit sweetness and flavor.
Owner:NANJING AGRICULTURAL UNIVERSITY

Glutamine synthetase high-efficiency expression vector with dual expression cassettes

The invention relates to a glutamine synthetase expression vector which can be amplified and have two expression cassettes. The main components of the glutamine synthetase expression vector include the following six parts: a first expression cassette component, a second expression cassette component, an f1 replicon, a glutamine synthetase expression cassette component, an ampicillin beta lactamase hydrolysis expression cassette component and a ColE1 replicon, wherein a strong enhancer/promotor CMV (Cytomegalovirus) and an immediate early enhancer/promotor are adopted to the first expression cassette component and the second expression cassette component; a weak promotor/enhancer SV40 is adopted to the glutamine synthetase expression cassette component, so that the expression of glutamine synthetase is reduced, and the screening of high-expression cloning is facilitated; and expression protein coding genes are respectively cloned to the expression vector through a multiple cloning site A and a multiple cloning site B. The glutamine synthetase expression vector disclosed by the invention is suitable for simultaneously expressing 1-2 proteins efficiently in mammalian cells and especially suitable for expressing antibody proteins.
Owner:BEIJING BIYANG BIOTECH

Method for constructing highly expressed trehalose synthase engineering bacteria by using Pcry3Aa promoter

The invention relates to a method for constructing highly expressed trehalose synthase engineering bacteria by using a Pcry3Aa promoter. For a recombinant carrier, a Pcry3Aa-PhoD fragment by which a Pcry3Aa promoter fragment and a PhoD signal peptide fragment are connected by an overlap PCR (Polymerase Chain Reaction) is inserted at the upstream of a restriction enzyme cutting site BamHI of a shuttle plasmid PHT01, and a target protein trehalose synthase TreS fragment is inserted between two restriction enzyme cutting site, i.e., BamHI and AatII. The invention further relates to a method for constructing the highly expressed trehalose synthase engineering bacteria by using the recombinant carrier. According to the method disclosed by the invention, the Pcry3Aa promoter is adopted to naturally induce the synthesis of trehalose synthase; because the Pcry3Aa promoter contains a special STAB-SD structure, the stability of the Pcry3Aa promoter to transcribe mRNA is improved, the half-life period of mRNA is prolonged, the mRNA translation level of a downstream target gene is improved, and therefore the trehalose synthase is highly expressed.
Owner:山东开盾生物科技有限公司

Heterocyclic modulators of lipid synthesis

Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and / or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatits C infection, cancer and metabolic disorders.
Owner:GANNEX PHARM CO LTD

Biosynthetic gene cluster of ikarugamycin and application of biosynthetic gene cluster

The invention discloses a biosynthetic gene cluster of ikarugamycin and an application of the biosynthetic gene cluster. The nucleotide sequence of the biosynthetic gene cluster of the ikarugamycin is as shown in the 3411th to 15678th sites of SEQ ID NO. 1 and contains three genes, namely a heterozygous polyketone / non-ribosomal polypeptide synthetase gene ikaA, FAD (Flavin Adenine Dinucleotide) dependent oxidoreductase gene ikaB and similar Michael cyclization reaction enzyme gene ikaC. All the genes and protein information relevant to the biosynthesis of the ikarugamycin are helpful to interpret the biosynthesis mechanism of natural products of a polycyclic tetramate large-ring lactam family so as to provide a theoretical basis and materials for further genetic modification. The genes and proteins can be used for digging or creating compounds or genes and proteins applicable to the medicine and health industry and industry and agriculture in nature.
Owner:SOUTH CHINA SEA INST OF OCEANOLOGY - CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products